| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Our resent studies revealed that natural compounds nybomycin are only effective to quinolone-resistant bacteria with mutations in the quinolone-resistant determining regions of their type IIA DNA topoisomerases. We designated such compound as reverse-antibiotic (RA). We have been interested in why nature produces RAs, and hypothesized that there should be many quinolone-resistant, or RA-susceptible bacteria (the targets of RA) in environment. To prove this hypothesis, we screened quinolone-resistant and RA-resistant bacteria from environmental samples, and found that many quinolone resistant bacteria were present in environment. Moreover, we also found that bacterial taxonomic families are strictly categorized into (1) quinolone-resistant and (2) RA-resistant groups. We also found that bacterial families to which human pathogens belong tend to be categorized in (2). This suggests that human pathogens have evolved by chance as quinolone-susceptible, explaining utility of quinolone.
|
